These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 21382486)

  • 1. HPV vaccination in France: uptake, costs and issues for the National Health Insurance.
    Fagot JP; Boutrelle A; Ricordeau P; Weill A; Allemand H
    Vaccine; 2011 Apr; 29(19):3610-6. PubMed ID: 21382486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France.
    Bergeron C; Largeron N; McAllister R; Mathevet P; Remy V
    Int J Technol Assess Health Care; 2008; 24(1):10-9. PubMed ID: 18218164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mathematical models of cervical cancer prevention in the Asia Pacific region.
    Goldie SJ; Diaz M; Kim SY; Levin CE; Van Minh H; Kim JJ
    Vaccine; 2008 Aug; 26 Suppl 12():M17-29. PubMed ID: 18945411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
    Goldie SJ; O'Shea M; Campos NG; Diaz M; Sweet S; Kim SY
    Vaccine; 2008 Jul; 26(32):4080-93. PubMed ID: 18550229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
    de Kok IM; van Ballegooijen M; Habbema JD
    J Natl Cancer Inst; 2009 Aug; 101(15):1083-92. PubMed ID: 19571256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human papillomavirus (HPV) vaccines: a Canadian update.
    Foerster V; Murtagh J
    Issues Emerg Health Technol; 2007 Dec; (109):1-8. PubMed ID: 18062141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preventing cervical cancer : overviews of the National Breast and Cervical Cancer Early Detection Program and 2 US immunization programs.
    Khan K; Curtis CR; Ekwueme DU; Stokley S; Walker C; Roland K; Benard V; Saraiya M
    Cancer; 2008 Nov; 113(10 Suppl):3004-12. PubMed ID: 18980296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of human papilloma virus (HPV) vaccination strategies and vaccination coverage in adolescent girls worldwide.
    Owsianka B; Gańczak M
    Przegl Epidemiol; 2015; 69(1):53-8, 151-5. PubMed ID: 25862448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human papillomavirus vaccines in Picardy, France: coverage and correlation with socioeconomic factors.
    Ganry O; Bernin-Mereau AS; Gignon M; Merlin-Brochard J; Schmit JL
    Rev Epidemiol Sante Publique; 2013 Oct; 61(5):447-54. PubMed ID: 24016739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age impact on human papillomavirus vaccination in France in 2014: A study from the National Health Insurance Database.
    Héquet D; Pouget N; Estevez JP; Robain M; Rouzier R
    Bull Cancer; 2015 Nov; 102(11):892-7. PubMed ID: 26526386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel method to value real options in health care: the case of a multicohort human papillomavirus vaccination strategy.
    Favato G; Baio G; Capone A; Marcellusi A; Saverio Mennini F
    Clin Ther; 2013 Jul; 35(7):904-14. PubMed ID: 23806328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human papillomavirus vaccine: a paradigm shift for pediatricians.
    Jenson HB
    Curr Opin Pediatr; 2009 Feb; 21(1):112-21. PubMed ID: 19242247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Insufficient basis for the inclusion of Human papillomavirus vaccination in the National Immunisation Programme in The Netherlands].
    de Kok IM; Habbema JD; Mourits MJ; Coebergh JW; van Leeuwen FE
    Ned Tijdschr Geneeskd; 2008 Sep; 152(37):2001-4. PubMed ID: 18825885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring the cost-effectiveness of HPV vaccination in Vietnam: insights for evidence-based cervical cancer prevention policy.
    Kim JJ; Kobus KE; Diaz M; O'Shea M; Van Minh H; Goldie SJ
    Vaccine; 2008 Jul; 26(32):4015-24. PubMed ID: 18602731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of human papilloma virus vaccination in Iceland.
    Oddsson K; Johannsson J; Asgeirsdottir TL; Gudnason T
    Acta Obstet Gynecol Scand; 2009; 88(12):1411-6. PubMed ID: 19900074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands.
    Boot HJ; Wallenburg I; de Melker HE; Mangen MJ; Gerritsen AA; van der Maas NA; Berkhof J; Meijer CJ; Kimman TG
    Vaccine; 2007 Aug; 25(33):6245-56. PubMed ID: 17630049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficiency of human papillomavirus vaccination--estimates based on Dutch cost effectiveness analyses].
    Westra TA; Daemen T; Postma MJ; Wilschut JC
    Ned Tijdschr Geneeskd; 2009; 153():A356. PubMed ID: 19930733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of sex-neutral HPV-vaccination in Sweden, accounting for herd-immunity and sexual behaviour.
    Wolff E; Elfström KM; Haugen Cange H; Larsson S; Englund H; Sparén P; Roth A
    Vaccine; 2018 Aug; 36(34):5160-5165. PubMed ID: 30017146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [HPV-infection].
    Schmidt-Petruschkat S
    MMW Fortschr Med; 2007 Mar; 149(12):29-31. PubMed ID: 17674887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention strategies against the human papillomavirus: the effectiveness of vaccination.
    Stanley M
    Gynecol Oncol; 2007 Nov; 107(2 Suppl 1):S19-23. PubMed ID: 17938013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.